home / stock / bglc / bglc news

BGLC News and Press, BioNexus Gene Lab Corp

Stock Information
Company Name: BioNexus Gene Lab Corp
Stock Symbol: BGLC
Market: NASDAQ
Website: bionexusgenelab.com
Menu
Get BGLC Alerts

News, Short Squeeze, Breakout and More Instantly...
BGLC - BioNexus Gene Lab Corp. Calls for Malaysia-China Biotechnology Cooperation to Move Beyond Trade into Co-Development

KUALA LUMPUR, Malaysia, May 29, 2026 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (Nasdaq: BGLC) (“BioNexus” or the “Company”), a technology-focused company advancing innovation across biotechnology, precision diagnostics, and emerging healthcare platforms, today high...
BGLC - BioNexus Gene Lab Corp. Announces Appointment of Dr. Muthu Meyyappan as Chief Commercial Officer of Fidelion Diagnostics to Lead Global Commercialization of the VitaGuard(TM) MRD Platform

KUALA LUMPUR, Malaysia, March 11, 2026 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (NASDAQ: BGLC) today announced that, in connection with its Fidelion Diagnostics Pte. Ltd (“Fidelion”) transaction, Dr. Muthu Meyyappan has been appointed Chief Commercial Officer of Fidelion. Fidelio...

BGLC - BioNexus Gene Lab Corp. Completes Chemrex Governance Restructuring; Appoints Matthew Barsing as Chairman

Enhanced board oversight aligns subsidiary with disciplined capital allocation and strategic evaluation framework KUALA LUMPUR, Malaysia, Feb. 23, 2026 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (Nasdaq: BGLC) (“BioNexus” or the “Company”), today announced the comp...

BGLC - BioNexus Launches Regional Deployment of VitaGuard(TM) MRD Infrastructure; Positioned to Challenge Legacy Oncology Platforms Across ASEAN's Multi-Billion Dollar Market

KUALA LUMPUR, Malaysia, Jan. 28, 2026 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (Nasdaq: BGLC) (“BioNexus” or the “Company”), a technology-driven precision diagnostics company, today announced the formal commencement of its 2026 Deployment Phase for the VitaGuard...
BGLC - BioNexus Gene Lab Corp. Completes Strategic Investment in Fidelion Diagnostics; Secures 15% Equity Stake in Global AI-Oncology Platform and Exclusive Southeast Asian Rights for VitaGuard(TM)

KUALA LUMPUR, Malaysia, Dec. 03, 2025 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (NASDAQ: BGLC) ("BGLC" or the "Company"), a biotechnology company advancing precision diagnostics and gene-based technologies, today announced the formal completion of its strategic transaction with Fidelion Diagnos...

BGLC - BioNexus Gene Lab Corp. (Nasdaq: BGLC) Secures $500 Million Equity Facility From ARC Group International to Support Expansion of Precision Diagnostics, CDMO Operations, and Therapeutic Commercialization

SHERIDAN, Wyo., Dec. 02, 2025 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (“ BGLC ” or the “ Company ”), an emerging provider of precision oncology diagnostics with expanding operations across Southeast Asia, today announced it has entered into a $500,000,0...

BGLC - BioNexus Gene Lab Corp. (Nasdaq: BGLC) and Fidelion Diagnostics Execute Exclusive Southeast Asia License for VitaGuard(TM) MRD Platform as Part of Strategic Alliance with Tongshu Gene

KUALA LUMPUR, Malaysia and SINGAPORE, Dec. 01, 2025 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (“BGLC”) today announced that it has executed an Exclusive Intellectual Property License Agreement for Southeast Asia with Fidelion Diagnostics Pte. Ltd. (“Fidelion”) fo...
BGLC - BioNexus Gene Lab Corp. (Nasdaq: BGLC) Announces Strategic Agreements with Fidelion Diagnostics for Southeast Asia MRD Commercialization

KUALA LUMPUR, Malaysia and SINGAPORE, Nov. 12, 2025 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (“ BGLC ,” Nasdaq: BGLC) today announced it has entered into definitive agreements with Fidelion Diagnostics Pte. Ltd. (“Fidelion”) and Tongshu Biotechnology (Hong K...

BGLC - BioNexus Gene Lab files $100M shelf registration and establishes $20M at-the-market program

2025-11-10 08:49:34 ET More on BioNexus Gene Lab Corp. Seeking Alpha’s Quant Rating on BioNexus Gene Lab Corp. Financial information for BioNexus Gene Lab Corp. Read the full article on Seeking Alpha For further details see: BioNexus Gene Lab files...

BGLC - BioNexus Gene Lab Corp. Files $100 Million Shelf Registration and Establishes $20 Million At-the-Market Program to Advance Strategic Growth Opportunities

KUALA LUMPUR, Malaysia, Nov. 10, 2025 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (Nasdaq: BGLC) (“BioNexus” or the “Company”), a biotechnology company advancing precision diagnostics and gene-based technologies across Asia and the U.S., today announced that it has fil...
Next 10